Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Ultragenyx Pharmaceutical (RARE) Assets Average: 2016-2025

Historic Assets Average for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Sep 2025 value amounting to $1.2 billion.

  • Ultragenyx Pharmaceutical's Assets Average fell 20.91% to $1.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year decrease of 20.91%. This contributed to the annual value of $1.5 billion for FY2024, which is 1.38% down from last year.
  • According to the latest figures from Q3 2025, Ultragenyx Pharmaceutical's Assets Average is $1.2 billion, which was down 4.64% from $1.3 billion recorded in Q2 2025.
  • Ultragenyx Pharmaceutical's Assets Average's 5-year high stood at $1.7 billion during Q1 2021, with a 5-year trough of $1.2 billion in Q3 2025.
  • For the 3-year period, Ultragenyx Pharmaceutical's Assets Average averaged around $1.4 billion, with its median value being $1.4 billion (2024).
  • In the last 5 years, Ultragenyx Pharmaceutical's Assets Average soared by 41.74% in 2021 and then dropped by 20.91% in 2025.
  • Quarterly analysis of 5 years shows Ultragenyx Pharmaceutical's Assets Average stood at $1.5 billion in 2021, then rose by 5.21% to $1.6 billion in 2022, then fell by 13.74% to $1.4 billion in 2023, then grew by 11.46% to $1.5 billion in 2024, then declined by 20.91% to $1.2 billion in 2025.
  • Its Assets Average was $1.2 billion in Q3 2025, compared to $1.3 billion in Q2 2025 and $1.4 billion in Q1 2025.